GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

sitagliptin, and vildagliptin [not FDA approved]), who were first prescribed one of these agents between January 2007 and December 2020. The second cohort included 32,336 GLP-1 receptor agonist ...

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic ... “CagriSema is an investigational fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...